Device Trial Radar · NCT07742839
CLAARITY is a Prospective, Observational, Single-arm, Multi-center, Post-market US Study Designed to Evaluate the Safety and Performance of the ECLIPTIS Left Atrial Appendage Exclusion System for Exclusion of the Left Atrial Appendage (LAA) During Concomitant Open-heart Cardiac Surgery.
Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
168
Planned (sponsor's estimate)
Start
Nov 30, 2026
Primary completion
Jul 10, 2027
Study completion Aug 29, 2030
Sponsor
- Lead sponsor
- Edwards LifesciencesPublic (EW)
- Sponsor type
- Industry
- First posted
- Aug 3, 2026
Design
- Study type
- Observational
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
CLAARITY is a prospective, observational, single-arm, multi-center, post-market US study designed to evaluate the safety and performance of the ECLIPTIS clip in a minimum of 168 participants.
Conditions
- Atrial Appendage
Interventions
Edwards ECLIPTIS Left Atrial Appendage Exclusion SystemDevice
Surgical placement of the Edwards ECLIPTIS Left Atrial Appendage Exclusion System
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of participants who have device technical successTime frame: Intra-operative
- Participant's rate of major clinically significant adverse eventsTime frame: 30 days
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.